Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3MIX-TATIN for necrotic primary molars
NCT03084601Phase 4
Key facts
- Status
- Completed
- Start
- Mar 2017
- Primary completion
- Jan 2018
- Countries
- 1
- Modality
- Small Molecules
- Drugs
- 3Mixtatin
- Conditions
- pulp necrosis
01
Overview
Phase 4, randomised trial of 3Mixtatin in pulp necrosis. Primary endpoint: Postoperative Pain at 3 months. Started Mar 2017; status: completed.
02
Design
- Study design
- Randomized
03
Who it enrols
Children aged 5-8 years with necrotic primary molars and radiographic evidence of furcation or periapical radiolucency, free from systemic diseases.
04
Endpoints
Primary
Postoperative Pain
Secondary
Gingival Swelling
Beyond the preview
Go deeper on NCT03084601.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03084601.